EyePoint shares are trading lower after the company announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU. The primary endpoint of change from baseline in best corrected visual acuity versus 2 mg aflibercept on-label control was not achieved in the full dataset.

Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.

EyePoint shares are trading higher after a Form 4 filing indicated that a company Director bought 10,600 shares at an average price of $4.93 per share.

RBC Capital Downgrades EyePoint to Sector Perform, Lowers Price Target to $5

RBC Capital analyst Lisa Walter downgrades EyePoint (NASDAQ:EYPT) from Outperform to Sector Perform and lowers the price target from $37 to $5.

Chardan Capital Downgrades EyePoint to Neutral, Lowers Price Target to $5

Chardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral and lowers the price target from $65 to $5.